Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update


IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases

NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy


NANOBOTIX (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo

Medigene AG: Medigene berichtet über Q3 2020
Medigene AG: Medigene berichtet über Q3 2020

Unternehmensmitteilung für den Kapitalmarkt

 

Planegg/Martinsried (12.11.2020) - Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten

Medigene AG: Medigene provides Q3 2020 update
Medigene AG: Medigene provides Q3 2020 update

Business news for the stock market

 

Planegg/Martinsried (12.11.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab


Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination

QIAGEN führt mobilen digitalen SARS-CoV-2-Antigentest mit hoher Genauigkeit und einer Analysekapazität von mehr als 30 Proben pro Stunde ein
QIAGEN führt mobilen digitalen SARS-CoV-2-Antigentest mit hoher Genauigkeit und einer Analysekapazität von mehr als 30 Proben pro Stunde ein


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat in den USA mit der Vermarktung eines mobilen digitalen Tests für Labore begonnen, mit dem ein Nachweis von SARS-CoV-2-Antigenen bei Menschen

Savara to Present at the Jefferies Virtual London Healthcare Conference : https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Present at the Jefferies Virtual London Healthcare Conference


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on

QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour
QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has started commercialization of a portable digital test in the United States that can be used by laboratories to detect SARS-CoV-2 antigens in

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Biopharmaceuticals Group, at the 2nd Annual Wolfe

Novocure Receives CE Mark for NovoTTF-100L™ System: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Receives CE Mark for NovoTTF-100L™ System


Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that it has received the CE Mark for the NovoTTF-100L

Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014, a highly selective, oral

Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced data presentations from clinical studies of QINLOCK, the Company’s switch-control tyrosine kinase inhibitor approved in the U.S. for

More Than 75 Companies Adopt Veeva Vault CTMS to Accelerate Clinical Research
More Than 75 Companies Adopt Veeva Vault CTMS to Accelerate Clinical Research


As the need to improve efficiency and speed in trials grows, more than 75 organizations, including six of the top 20 pharmaceutical companies, are unifying clinical information and processes with

Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimenshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens


Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE REGIMEN study. This 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1

Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2


Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2

ICON Releases First Environmental, Social and Governance Report: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Releases First Environmental, Social and Governance Report


ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

NanoString Highlights Growing Body of Spatial Biology Research Presented at the 35th Annual Meeting of the Society of Immunotherapy of Cancer Conference (SITC): https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Highlights Growing Body of Spatial Biology Research Presented at the 35th Annual Meeting of the Society of Immunotherapy of Cancer Conference (SITC)


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of more than 35 NanoString-related

Quidel to Present at Upcoming Conferences
Quidel to Present at Upcoming Conferences


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the

Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent

Cano Health and Humana Relationship Expands Access to Health Care for Seniors in San Antonio and Las Vegas: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Cano Health and Humana Relationship Expands Access to Health Care for Seniors in San Antonio and Las Vegas


Cano Health, a senior-focused primary care group led by physicians, and leading health and well-being company Humana (NYSE: HUM) have teamed up to offer seven new health centers to serve Medicare

Prime Healthcare and Humana Announce Network Agreements for Providence Medical Center and Saint John Hospital in Kansas: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Prime Healthcare and Humana Announce Network Agreements for Providence Medical Center and Saint John Hospital in Kansas


Leading health care system Prime Healthcare and leading health and well-being company Humana Inc. (NYSE: HUM) today announced agreements that provide in-network access for most area Humana Medicare

LivaNova to Present at the Stifel 2020 Virtual Healthcare Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present at the Stifel 2020 Virtual Healthcare Conference


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare

DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment


DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that the DILIsym

Novocure Announces Agenda for Virtual Research and Development Day: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Agenda for Virtual Research and Development Day


Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EST on Thursday, November 12, 2020

IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced the